文献速递精神分裂症与精神病性障碍

经皮耳迷走神经刺激治疗以阴性症状为主的精神分裂症难治性患者的疗效与安全性:随机临床试验及疗效敏感性生物标志物

Efficacy and safety of transcutaneous auricular vagus nerve stimulation for patients with treatment-resistant schizophrenia with predominantly negative symptoms: a randomized clinical trial and efficacy sensitivity biomarkers.
PubMed 文献 · Mol Psychiatry · 2025-08-26

该双盲假对照随机临床试验纳入50例以阴性症状为主的精神分裂症难治性(TRS)患者,比较2周活性经皮耳迷走神经刺激(taVNS)与假刺激的疗效。意向性分析显示活性组PANSS阴性症状因子分改善显著优于假刺激组(差值-1.36,效应量-0.62,95%CI -1.20至-0.04,p=0.033),随访期效果持续且耐受性良好。TNF-α变化及左额顶β频段相干性与阴性症状改善相关,或为疗效敏感性生物标志物。

要点

  • taVNS辅助治疗可显著改善TRS患者阴性症状,效应量-0.62,随访期持续。
  • TNF-α变化与左额顶β频段相干性变化与阴性症状改善相关。
  • taVNS耐受性良好,可作为TRS阴性症状的辅助治疗选择。

核心结论

  • taVNS可能有效且安全地改善以阴性症状为主的TRS患者的阴性症状。
  • TNF-α及左额顶β频段相干性可能为taVNS疗效的敏感性生物标志物。

研究设计与样本

  • 双盲、假对照、随机临床试验,纳入50例以阴性症状为主的TRS患者,活性taVNS组25例、假taVNS组25例。
  • 干预2周后随访2周,主要结局为干预后PANSS阴性症状因子分(PANSS-FSNS)变化。

主要发现

  • 意向性分析中,活性taVNS组PANSS-FSNS改善显著优于假刺激组(差值-1.36,效应量-0.62,95%CI -1.20至-0.04,p=0.033)。
  • 疗效在随访期持续,且耐受性良好。
  • 活性组中PANSS-FSNS变化与TNF-α变化显著相关(r=0.56,校正p=0.017)。
  • 活性组中PANSS-FSNS变化与左额顶β频段相干性变化显著相关(r=-0.56,p=0.004),假刺激组无此相关。

关键数值与推荐

  • 主要疗效指标PANSS-FSNS组间差值-1.36,效应量-0.62,95%CI -1.20至-0.04,p=0.033。
  • TNF-α变化与PANSS-FSNS变化相关r=0.56,校正p=0.017。
  • 左额顶β频段相干性变化与PANSS-FSNS变化相关r=-0.56,p=0.004。

临床怎么用

  • taVNS可作为以阴性症状为主的TRS患者的辅助治疗选择,尤其关注阴性症状改善。
  • TNF-α及左额顶β频段相干性变化或可用于监测taVNS疗效敏感性。

局限性

  • 样本量较小(共50例),干预及随访时间较短(2周干预+2周随访)。
  • 疗效敏感性生物标志物结果需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Negative symptoms in treatment-resistant schizophrenia (TRS) are notably persistent and minimally affected by antipsychotics, the transcutaneous auricular vagus nerve stimulation (taVNS) is a promising treatment approach. However, clinical trials are scarce, and further efficacy data are needed. We conducted a double-blind, sham-controlled, randomized clinical trial to determine the efficacy and safety of taVNS as an add-on treatment for patients with TRS with predominantly negative symptoms and to investigate potential biomarkers of efficacy. A total of 50 patients underwent a two-week intervention of active taVNS (n = 25) or sham taVNS (n = 25), followed by a two-week follow-up. Primary outcome was the change in the PANSS-factor score for negative symptoms (PANSS-FSNS) assessed after the intervention. In the intention-to-treat analysis, patients receiving active taVNS showed a significantly greater improvement in negative symptoms compared with those receiving the sham procedure (PANSS-FSNS difference, -1.36; effect size, -0.62; 95% CI, -1.20 to -0.04; p = 0.033), with effects sustained at follow-up and good tolerability. Inflammatory cytokines and EEG coherence showed that in the active group, the change in PANSS-FSNS scores after treatment was significantly correlated with changes in tumour necrosis factor (TNF)-α (r = 0.56, corrected p = 0.017) and beta-band coherence between the left frontal and parietal regions (r = -0.56, p = 0.004), but not in the sham group. This study suggests that taVNS may effectively and safely ameliorate negative symptoms in TRS, with TNF-α and beta-band coherence between the left frontal and parietal regions as potential sensitivity efficacy biomarkers. Chinese Clinical Trial Registry ( http://www.chictr.org.cn .), ChiCTR2400085198.

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Cui Y, Sun J, Zhang B, et al. Efficacy and safety of transcutaneous auricular vagus nerve stimulation for patients with treatment-resistant schizophrenia with predominantly negative symptoms: a randomized clinical trial and efficacy sensitivity biomarkers. Mol Psychiatry. 2025. PMID: 40858781. doi:10.1038/s41380-025-03132-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。